Brandon Imber, MD, MA
Lymphomas; Intensity Modulated Radiation Therapy (IMRT); Image-Guided Radiation Therapy (IGRT); Volumetric Arc Therapy (VMAT); Stereotactic Body Radiation Therapy (SBRT); Stereotactic Radiosurgery (SRS); MSK Precise for Brain Cancer
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MA, Chemical Biology, Harvard University; MD, University of California, San Francisco School of Medicine; Certificate Program in Clinical Effectiveness, Harvard University T.H. Chan School of Public Health
Radiation Oncology - Memorial Sloan Kettering Cancer Center
Lymphoma Radiotherapy - Memorial Sloan Kettering Cancer Center
I am a radiation oncologist who cares for people with blood cancers and tumors affecting the brain and central nervous system. I see patients in Manhattan and our Regional Care Network on Long Island. As a graduate of Commack High School, I feel fortunate to be able to offer compassionate, state-of-the-art care to the communities where I grew up.
I received my bachelor’s and master’s degrees in chemistry from Harvard University. I earned my medical degree at the University of California, San Francisco, dedicating an additional year to research focused on the aggressive brain cancer glioblastoma. My specialty training was at Memorial Sloan Kettering, where I also completed a clinical research fellowship in lymphoma radiation oncology. As a resident, I obtained specialized training in clinical research at the Harvard School of Public Health.
I was drawn to oncology, and radiation oncology specifically, because of the strong bonds formed between patient and physician. A cancer diagnosis and the prospect of radiation therapy can be intimidating, overwhelming, and frightening. I believe that critical first steps are to communicate clearly to ease fears, provide full explanations of options, and answer questions. My team and I strive to be our patients’ unwavering advocates and aim to offer strong emotional and physical support at every step of the process.
When treating blood cancers like lymphoma, multiple myeloma, and leukemia, as well as certain brain tumors, I implement advanced radiation techniques including intensity modulated radiation therapy and image-guided radiation therapy to safely and effectively treat these cancers. For brain metastases and benign tumors, I often rely on highly focal modalities like MSK Precise™ stereotactic radiosurgery.
I am a strong believer in a multidisciplinary approach to patient care and am a member of several clinical teams, including the Lymphoma Disease Management Team and MSK’s Brain Metastasis Center. I work collaboratively with my patients’ other providers, including medical oncologists, surgeons, radiologists, and pathologists to develop a highly personalized care plan guided by the latest clinical evidence. I feel very strongly that patients and their families should be participants in this process to tailor the treatment plan according to specific goals and concerns.
In addition to caring for patients, I participate in several research programs which fall under two broad themes: improvement of outcomes and reduction of side effects for blood and brain cancer treatments. I am particularly interested in designing clinical trials which combine radiotherapy with other novel cancer therapies. For example, I am currently studying potential ways to combine radiation with highly innovative CAR T cell therapies to enhance treatment responses in aggressive lymphomas like diffuse large B-cell lymphoma. To minimize side effects and increase patient convenience, I am studying how we can safely reduce the number of radiation treatments necessary for less-aggressive lymphomas like cutaneous T-cell lymphomas. I am also working closely with colleagues in neurosurgery and neuro-oncology to evaluate new technologies for brain brachytherapy, a specialized way to deliver radiation in the operating room very focally to the edges of a surgical cavity while sparing much of the surrounding healthy brain tissue.
I feel privileged to practice at MSK given our ability to offer world-class treatment approaches including promising clinical trials which might not be available elsewhere. When I am not working, I enjoy spending time with my family, brewing craft coffee, running in Central Park, and hiking in upstate New York.
My team and I strive to be our patients’ unwavering advocates and aim to offer strong emotional and physical support at every step of the process.
Awards and Honors
- Chief Resident, Radiation Oncology, Memorial Sloan Kettering Cancer Center (2020)
- Abstract Award, American Society of Hematology (2019)
- Resident Research Grant, American College of Radiation Oncology (2018)
- Dr. Mortimer J. Lacher, MD Fellowship award in Lymphoma, Memorial Sloan Kettering Cancer Center (2018)
- Resident Essay Award, American College of Radiation Oncology (2017)
- Alpha Omega Alpha Medical Honor Society, UCSF (2014)
- Clinical Trials Co-Investigated by Dr. Imber
- A Phase IB Study of Bexarotene Combined with Radiotherapy in People with Mycosis Fungoides
- A Phase II Study of Stereotactic Body Radiation Therapy and Radium Dichloride to Treat Prostate Cancer that Has Spread to the Bones
- A Phase II Study of Stereotactic Radiosurgery for People with Small Cell Lung Cancer that Spread to the Brain
- A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 to Treat Prostate Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Imber’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Brandon Imber discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.